Morphine Sulfate (Morphine Sulfate) Patent Expiration, LOE Window & CMS Spending

Morphine Sulfate (Morphine Sulfate) by Hikma Pharmaceuticals: FDA Orange Book LOE 2034-03-12, 3 AB generics, $88.0M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN022195 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-12
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$88.0M
2024 Medicare Part D Spend$17.1M
2024 Medicaid Spend$71.0M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 119.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.